Skip to main content

Table 1 Baseline demographic and clinical characteristics (ITT population)

From: A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients

Parametera IC43 100 μg with adj
N = 104
IC43 100 μg w/o adj
N = 98
IC43 200 μg with adj
N = 101
Placebo
N = 98
Total
N = 401
Age (years) 57.0 (16.2) 54.3 (15.3) 55.2 (15.7) 58.1 (15.3) 56.1 (15.6)
Weight (kg) 82.0 (19.2) 84.6 (17.6) 82.5 (17.9) 82.5 (21.7) 82.9 (19.1)
Height (cm) 170.8 (10.5) 173.5 (9.1) 171.5 (8.2) 171.5 (10.0) 171.8 (9.5)
Sex
 Male 64 (61.5) 70 (71.4) 72 (71.3) 61 (62.2) 267 (66.6)
 Female 40 (38.5) 28 (28.6) 29 (28.7) 37 (37.8) 134 (33.4)
Race
 Caucasian 95 (91.3) 93 (94.9) 94 93.1) 92 (93.9) 374 (93.3)
 Asian 2 (1.9) 1 (1.0) 0 (0.0) 2 (2.0) 5 (1.2)
 Black 1 (1.0) 0 (0.0) 2 (2.0) 1 (1.0) 4 (1.0)
 Other 6 (5.8) 4 (4.1) 5 (5.0) 3 (3.1) 18 (4.5)
HIV status
 Positive 0 (0.0) 2 (2.0) 0 (0.0) 0 (0.0) 2 (0.5)
 Missing 2 (1.9) 1 (1.0) 3 (3.0) 3 (3.1) 9 (2.2)
  1. aData are presented as mean (standard deviation) for age, weight and height, and number (%) of patients for sex, race, and HIV status. HIV human immunodeficiency virus, ITT intention-to-treat, w/o adj without aluminum hydroxide adjuvant, with adj with aluminum hydroxide adjuvant